Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hyperlipoproteinemia Type III

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Hyperlipoproteinemia Type III. Displaying page 1 of 1.
    EudraCT Number: 2021-003280-95 Sponsor Protocol Number: ISIS678354-CS13 Start Date*: 2022-06-16
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: An Open-Label Extension Study of AKCEA-APOCIII-LRX Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)
    Medical condition: Familial Chylomicronemia Syndrome (FCS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10059183 Familial hypertriglyceridaemia PT
    20.1 100000004861 10020607 Hyperchylomicronemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Trial now transitioned) NO (Completed) PT (Trial now transitioned) FR (Trial now transitioned) SK (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-000582-37 Sponsor Protocol Number: CHOL00107 Start Date*: 2007-09-21
    Sponsor Name:Genzyme Europe BV
    Full Title: A Phase 4 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Study of Colesevelam as Add-on Therapy in Patients with Familial Hypercholesterolaemia
    Medical condition: Familial hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049593 Familial hypercholesterolaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FR (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-002192-19 Sponsor Protocol Number: ISIS678354-CS5 Start Date*: 2022-07-22
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia
    Medical condition: Severe hypertryglyceridemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10059183 Familial hypertriglyceridaemia PT
    20.1 100000004861 10020607 Hyperchylomicronemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) HU (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) FI (Trial now transitioned) BG (Trial now transitioned) SK (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002997-28 Sponsor Protocol Number: ISIS304801-CS20 Start Date*: 2021-03-17
    Sponsor Name:Akcea Therapeutics, Inc.
    Full Title: An Open-Label Study of Volanesorsen (ISIS 304801) Administered Subcutaneously to Pediatric Patients with Familial Chylomicronemia Syndrome (FCS)
    Medical condition: Familial Chylomicronemia Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10020606 Hyperchylomicronaemia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004084-31 Sponsor Protocol Number: 1002-041 Start Date*: 2023-01-23
    Sponsor Name:Esperion Therapeutics, Inc.
    Full Title: AN OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF BEMPEDOIC ACID IN PEDIATRIC PATIENTS (6 TO 17 YEARS OF AGE) WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    Medical condition: HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    Disease: Version SOC Term Classification Code Term Level
    21.0 10027433 - Metabolism and nutrition disorders 10020604 Hypercholesterolemia LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10054380 Familial hypercholesterolemia LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10057079 Heterozygous familial hypercholesterolemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Ongoing) NL (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-002889-11 Sponsor Protocol Number: D3560C00071 Start Date*: 2005-11-04
    Sponsor Name:AstraZeneca AB
    Full Title: An 18-Week, Randomized, Multicenter, Phase IIIb, Double-Blind, Crossover Study, Followed by an 18-Week Open-Label Period to Evaluate the Efficacy and Safety of the Lipid-Regulating Agents, Rosuvast...
    Medical condition: Dysbetalipoproteinemia (Fredrickson Type III Hyperlipoproteinemia)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: View results
    EudraCT Number: 2022-001135-85 Sponsor Protocol Number: AROAPOC3-2003 Start Date*: 2022-09-06
    Sponsor Name:Arrowhead Pharmaceuticals, Inc.
    Full Title: A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia
    Medical condition: Mixed Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    26.0 100000004850 10027763 Mixed hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-006557-28 Sponsor Protocol Number: FENOPRA-III-06-1 Start Date*: 2007-05-07
    Sponsor Name:Laboratoires SMB S.A.
    Full Title: A phase III, four-armed, randomised, double blind, parallel study to compare the efficacy and safety in type 2 diabetic patients with combined hyperlipidemia of a 12-week administration of Fenofibr...
    Medical condition: Type 2 diabetic patients, as defined by the WHO without CVD and with CVD (Cardiovascular disease), with combined hyperlipidemia.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027763 Mixed hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000688-57 Sponsor Protocol Number: AROAPOC3-2002 Start Date*: 2021-11-10
    Sponsor Name:Arrowhead Pharmaceuticals, Inc.
    Full Title: A Double-blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Mixed Dyslipidemia
    Medical condition: Mixed Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10027763 Mixed hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-000037-19 Sponsor Protocol Number: 0524B-024 Start Date*: 2008-07-15
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK-0524B (dosed as coadministered MK-0524A and Simvastatin Tablets) Versus Atorvastatin...
    Medical condition: Mixed Hyperlipidemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027763 Mixed hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) ES (Completed) SE (Completed) GB (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2015-003755-21 Sponsor Protocol Number: ISIS304801-CS7 Start Date*: 2016-06-06
    Sponsor Name:Akcea Therapeutics
    Full Title: An Open-Label Study of Volanesorsen Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)
    Medical condition: Familial Chylomicronemia Syndrome (FCS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10017339 Fredrickson Type I lipidaemia LLT
    20.0 100000004850 10060593 Fredrickson Type I lipidemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) ES (Completed) DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002421-35 Sponsor Protocol Number: ISIS304801-CS6 Start Date*: 2014-10-27
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)
    Medical condition: Familial Chylomicronemia Syndrome (FCS)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10017339 Fredrickson Type I lipidaemia LLT
    18.1 100000004850 10060593 Fredrickson Type I lipidemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Feb 11 03:26:54 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA